In addition, new approvals further boost portfolio. are treated with Apoquel or Cytopoint, up from 52% in the first quarter. Latest data shows that 55% of dogs with dermatology problems in the U.S. The company expects to witness stronger growth from its companion animal portfolio in 2017 driven by its dermatology portfolio, Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Apoquel and other product launches continue to drive growth in companion animal portfolio. The company continues to strengthen its diverse portfolio of products through lifecycle innovations, strong customer relationships, and access to new markets and technologies. Zoetis derives a majority of its revenues from a diversified product portfolio of medicines and vaccines that are used to treat and protect livestock and companion animals. Zoetis markets its offerings primarily across eight core species – cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals). The company’s business is divided into five categories – anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. Zoetis boasts a robust and diversified product portfolio. ( ZTS Quick Quote ZTS - Free Report) on Aug 18. We issued an updated report on Zoetis, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |